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Mononuclear phagocytes often function as control switches of the immune system, securing the balance between pro- and anti-
inﬂammatory reactions. For this purpose and depending on the activating stimuli, these cells can develop into diﬀerent subsets:
proinﬂammatory classically activated (M1) or anti-inﬂammatory alternatively activated (M2) macrophages. The expression of the
nuclear peroxisome proliferator-activated receptors (PPARs) is regulated by M1- or M2-inducing stimuli, and these receptors are
generally considered to counteract inﬂammatory M1 macrophages, while actively promoting M2 activation. This is of importance
in a tumor context, where M1 are important initiators of inﬂammation-driven cancers. As a consequence, PPAR agonists are
potentially usefull for inhibiting the early phases of tumorigenesis through their antagonistic eﬀect on M1. In more established
tumors, the macrophage phenotype is more diverse, making it more diﬃcult to predict the outcome of PPAR agonism. Overall,
in our view current knowledge provides a sound basis for the clinical evaluation of PPAR ligands as chemopreventive agents in
chronic inﬂammation-associated cancer development, while cautioning against the unthoughtful application of these agents as
cancer therapeutics.
Copyright © 2008 Jo A. Van Ginderachter et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
For many years, the centre of gravity in cancer research was
focused on uncovering the activating (oncogenes) and/or
deactivating (tumor suppressor genes) mutations in pro-
liferating cells, causing these cells to adopt a cancerous
phenotype [1]. By now, it has become increasingly clear
that untransformed host cells, in particular cells of the
immune system, are equally important in every aspect of
cancer, from tumor initiation and progression to metastasis
formation. Chronic inﬂammation, in response to microbial
infections or persistent chemical insults, may provoke DNA
damage in the surrounding tissue and induce cellular trans-
formation [2–5]. Newly transformed cells can be eliminated
or kept in a dormant state under the control of innate
and adaptive immune cells, but ultimately the surviving
“immunoedited” cancer cells are less immunogenic and
more aggressive [6, 7]. Within the organoid context of a
tumor, normal physiological functions of stromal cells—
including a large fraction of leukocytes—are harnessed in
favour of tumour progression, leading to modiﬁcations in
the local extracellular matrix, neoangiogenesis, stimulation
of cancer cell proliferation, and survival and promotion of
cancer cell motility and invasiveness [8]. In each of these
aspectsofthetumor/immuneinterface,cellsbelongingtothe
mononuclear phagocyte system (including lineage commit-
ted bone marrow precursors, monocytes, and macrophages)
havebeenimplicated,functioningindiﬀerentcompartments
(tumor site, periphery) and, mainly dictated by the context,
having the potential to contribute to such diametrically
opposed processes as tumor destruction or tumor promo-
tion. The latter stresses the heterogeneity and polyvalency of
this type of cells, making them indispensable for develop-
ment,tissuehomeostasis,inﬂammation,pathogenclearance,
and wound healing [9]. As a consequence, drugs with the
capacityofmodifying macrophageactivationareofpotential
interest in the treatment of diﬀerent pathologies, including
cancer. One such class of drugs is the ligands for peroxisome
proliferator-activated receptors (PPARs), which are ligand-
activated transcription factors belonging to the nuclear
hormone receptor superfamily. The three PPAR isoforms
(PPARα,P P A R β/δ,a n dP P A R γ)a r ee n c o d e db yd i ﬀerent
genes and display diﬀerences in their tissue distribution,
suggestiveofspecializedfunctions.Uponheterodimerization2 PPAR Research
with retinoid X receptors (RXRs), PPARs bind to speciﬁc
responseelements(PPREs)inthepromoterregionsofawide
array of PPAR-regulated genes. As a consequence, PPARs
have a broad range of eﬀects on metabolism, cellular prolif-
eration, diﬀerentiation, and immunity [10]. Of importance
in the context of this review, each of the PPAR isoforms
is expressed in cells of the monocyte/macrophage lineage
and inﬂuences the phenotype of these cells [11–13]. This
knowledge, in combination with the potential impact of
monocytes/macrophages on tumor development, provides a
rationale for investigating the modulation of PPAR activity
in mononuclear phagocytes as therapeutic strategy in cancer
research.
2. PLASTICITY OF MACROPHAGE ACTIVATION
2.1. TheM1/M2conceptualframeof
macrophageactivation
Macrophages belong to the most versatile cells of the
body. Heterogeneity arises as macrophages diﬀerentiate
from monocyte precursors and is determined by the
g e n e t i cb a c k g r o u n da sw e l la sb ys p e c i ﬁ ct i s s u e - r e l a t e da n d
immune-related stimuli [9, 14]. In this regard, microbial
antigens, tumor products, immune complexes as well as
Th1 or Th2 eﬀector T cells and their secretory products
inﬂuence the heterogeneity and the state of activation
of macrophage populations [15, 16]. The better charac-
terized response of macrophages to microbial molecules,
cancer cells, and host cytokines is the release of inﬂam-
matory/microbicidal/tumoricidal products. This “classical
activation” proﬁle occurs in a type I cytokine environment
(IFN-γ,T N F α) or upon recognition of pathogen-associated
molecular patterns (LPS, lipoproteins, dsRNA, lipoteichoic
acid, etc.) and endogenous “danger” signals (heat shock
proteins, extracellular matrix components, HMGB1, etc.)
[17]. As such, it plays an important role in protection
againstintracellularpathogens,andundercertainconditions
also cancer cells. Classically activated macrophages or M1
typically produce high levels of IL-12 and IL-23 [18]
combined with low levels of IL-10 and are consequently
strong promotors of Th1 immune responses. In addition,
these cells exert antiproliferative and cytotoxic activities,
resulting partly from their ability to secrete reactive nitrogen
and oxygen species (NO, peroxynitrite, hydrogen peroxide,
superoxide) and proinﬂammatory cytokines (TNF, IL-1, IL-
6) [19–22]. Although such short-term inﬂammatory activity
could be beneﬁcial for the host in a tumor setting, the persis-
tence of inﬂammatory processes often results in detrimental
tissue and DNA damage contributing to cancer development
[2–5]. Therefore, in the course of a response, inﬂammation
is usually counteracted through the development of anti-
inﬂammatory mechanisms. Ideally, this regulation must be
spatially and temporally controlled.
Distinct mediators have been reported to inhibit the
development of M1 and impart anti-inﬂammatory prop-
erties on macrophages, which were collectively termed
“alternatively activated” or M2: Th2 cytokines, such as IL-
4 and IL-13, deactivating cytokines, such as IL-10 and
TGF-β, hormones, such as the glucocorticoids and vitamin
D3, and apoptotic cells [23]. M2 have been reported
to actively contribute to the pathology of helminth and
protozoan infections, but also cancer [24–28]. The hetero-
geneity of these anti-inﬂammatory macrophages, whereby
each stimulus induces both unique and overlapping gene
expression repertoires, has urged the need for a more
reﬁned nomenclature. Gordon and colleagues proposed
to restrict the deﬁnition of “alternative activation” to IL-
4 and/or IL-13-elicited macrophages [29]. Subsequently,
Mantovani and coworkers used a high production of IL-10
and low production of IL-12 as unifying theme for M2 [15].
Following this logic, a further subdivision was suggested
between M2a, b, and c, representing IL-4/IL-13-stimulated
(alternatively activated sensu strictu), immune complexes +
TLR ligand-stimulated [30], and IL-10-stimulated (deacti-
vated) macrophages, respectively. Though a usefull working
scheme, it should be realised that any form of classiﬁcation
underscores the complexity of the in vivo situation, where
macrophages are exposed to mixtures of stimuli and will
adopt mixed functional proﬁles accordingly. This is exempli-
ﬁed by the determination of a consensus gene signature for
in vivo induced M2 in diﬀerent pathologies, which contains
genes that are not inducible in vitro by any of the known M2
inducing stimuli [31].
2.2. ImpactofPPARsonthemacrophage
activationstate
All three isoforms of PPAR have been reported to be consti-
tutively expressed in macrophages, with their mRNAs being
upregulated during monocyte to macrophage diﬀerentiation
[11,32–34].Thoughnotallreportsareinagreement,PPARγ,
but not PPARα or -β/δ, may actually promote macrophage
diﬀerentiation and contribute to the development of typical
macrophage-associated features, such as phagocytosis of
apoptotic cells [33–36]. The further regulation of PPARs in
M1- or M2-conditioning environments has been thoroughly
investigatedinthecaseofPPARγ.PP ARγ mRNAandprotein
are strongly induced in resident peritoneal macrophages and
peripheral blood monocytes by the typical M2 inducers IL-
4 and vitamin D3, suggesting a preferential association of
high PPARγ activity with M2 [33, 37]. Indeed, M1 stimuli
such as IFNγ,L P S ,T N F α,o rI L - 1 β either have no eﬀect on
PPARγ expression or were even inhibitory [37, 38]. On top
of a higher level of PPARγ receptors, M2 also produce more
endogenousPPARγ ligands,inpartasaconsequenceofIL-4-
mediated induction of 12/15 lipoxygenase [37, 39, 40]. This
lipid-peroxidating enzyme generates the PPARγ ligands 13-
HODE and 15-HETE through the oxygenation of linoleic
acid and arachidonic acid, respectively [40, 41]. In addition,
both in mouse peritoneal macrophages and in human
monocytes, IL-13 is able to increase the production and the
nuclear localization of the PPARγ ligand 15-deoxy-Δ12,14-
prostaglandin J2 (15d-PGJ2) by a mechanism dependent on
phospholipase A2 activation [42, 43].
Very few data are available on PPARα gene regulation
by pro- or anti-inﬂammatory stimuli, with only one study
demonstrating a relatively unaltered PPARα mRNA contentJo A. Van Ginderachter et al. 3
in macrophages upon LPS treatment [44]. In general,
systemic LPS treatment tends to decrease overall PPARα
expression levels, though it is unclear whether macrophages
account for this phenomenon [45].
In the case of PPARβ/δ,current data suggest that this
gene could be upregulated in both M1 and M2 polarizing
conditions.Ontheonehand,PPARβ/δ mRNAisupregulated
by LPS in macrophages, suggesting an association with M1
[44]. In keratinocytes, LPS and inﬂammatory cytokines not
only induce PPARβ/δ gene transcription through an AP-
1 site in the promoter, but also initiate the production of
endogenous PPARβ/δ ligands [46, 47]. Of importance, the
anti-inﬂammatory cytokine TGF-β1 counteracts PPARβ/δ
expression in these cells [47]. This dynamic control of
PPARβ/δ expressionisparticularlyimportantintissueinjury
and wound control [48]. If extendible to macrophages, these
data would imply an enhanced PPARβ/δ transcriptional
activity in an M1 context. On the other hand, in a very recent
paper, IL-4 and IL-13 were shown to induce macrophage
PPARβ/δ expression through a STAT6 binding site on its
promoter [49]. Taken together, PPARβ/δ could be unique in
its capacity to contribute to both M1 and M2 characteristics.
2.3. PPARsandM1activationofmacrophages
In macrophages, numerous inﬂammatory signalling path-
ways downstream of cytokine receptors or pattern recogni-
tion receptors orchestrate the inﬂammatory process. Central
players in these signalling cascades are the NF-κB, AP-1,
and STAT family of transcription factors, whose binding
sites can be found in the promoters of inﬂammatory
cytokines, chemokines, metalloproteinases, iNOS, and other
inﬂammatory genes [50, 51].
2.3.1. PPARγ
PPARγ agonists dose-dependently inhibit the upregulation
of inﬂammatory genes in macrophages in response to Toll-
like receptor ligands and interferons. These eﬀects are at least
partially PPARγ-dependent and can be attributed to an inhi-
bition of NF-κB, AP-1, and STAT1 transcriptional activities
[52–54]. By now, the molecular machinery behind PPARγ-
mediated repression of NF-κB-regulated genes has been
uncovered and appears to depend on a mechanism termed
ligand-dependent transrepression [55, 56]. Under steady-
state conditions, some genes (e.g., iNOS) are occupied and
actively repressed by the multisubunit NCoR repressor com-
plex.UponNF-κBactivation,theNCoRcomplexisdegraded
by the proteasome, NF-κB p65-p50 heterodimers enter the
nucleus, bind to NF-κB elements in the promoter, and
recruit coactivator complexes to initiate gene transcription.
However, simultaneous ligand binding of PPARγ leads to
SUMOylation of a fraction of the PPARγ molecules, which
bind to NCoR and prevent its clearance from the promoter,
leading to a sustained repressed state [57]. The requirement
for the NCoR corepressor complex explains why only a
subset of LPS-inducible genes is truely PPARγ-regulated
[54]. Remarkably, also AP-1-mediated gene transcription
depends on the loss of NCoR complexes, suggesting a
similar mechanism of PPARγ-mediated repression of AP-1-
regulated genes [58]. Of note, PPARγ agonists such as 15d-
PGJ2 and thiazolidinediones suppress a broaderrange of NF-
κB-regulated genes, irrespective of their NCoR dependence,
and are even able to do so in PPAR null macrophages
[54, 59]. In the case of 15d-PGJ2, this can be explained by a
direct, PPARγ-independent modiﬁcation of critical cysteine
residues in the IκB kinase and the DNA-binding domains of
NF-κB subunits, inhibiting NF-κBa c t i v i t y[ 60, 61].
The in vivo relevance of macrophage-expressed PPARγ
in attenuating inﬂammation has been demonstrated in
macrophage-speciﬁc PPARγ−/− animals. Unstimulated
macrophages from these mice display an increased
production of inﬂammatory mediators, indicating that
endogenous PPARγ ligands modulate macrophages under
steady-state conditions. In addition, PPARγ−/− macrophage
recruitment to inﬂammatory sites is increased, and these
macrophages overreact to inﬂammatory stimuli, resulting
in increased severity of DSS-induced colitis [62]. Of
importance, thiazolidinediones still improve colitis severity
in colonic epithelium-speciﬁc PPARγ−/− mice, but not
in macrophage-speciﬁc PPARγ−/− mice, suggesting that
macrophages are the relevant targets of these compounds
in this disease [63]. Also in models of insulin resistance and
atherosclerosis, macrophage-speciﬁc PPARγ was shown to
inhibit inﬂammation and improve insulin sensitivity and
reduce atherosclerotic lesion size, respectively [64, 65].
2.3.2. PPARα
PPARα ligands are able to lower the secretion of inﬂamma-
tory mediators in several cell types, including macrophages
[66–70] .S i m i l a rt oP P A R γ,P P A R α is able to transrepress
NF-κB and AP-1 transcriptional activity, though it does
so in a diﬀerent way. Inhibition of these transcription
factors by PPARα is independent of the promoter context
but appears to depend on a physical interaction between
PPARα and the p65 Rel homology domain or the JNK-
responsive part of c-Jun [71]. In addition, ligand-bound
PPARα transactivates the IκBα promoter in a DNA binding-
independent fashion, as such further attenuating NF-κB
activation [72]. Another parallel with PPARγ is the impor-
tance of posttranslational modiﬁcations in the activity of
PPARα. Inﬂammatory stimuli such as LPS activate protein
kinase C (PKC), which subsequently phosphorylates and
inactivates PPARα. However, statins inhibit PKC activation,
increasing the pool of unphosphorylated transrepression-
competent PPARα which is entirely responsible for the
anti-inﬂammatory activity of statins [73]. Also the well-
characterised anti-inﬂammatory potential of glucocorticoids
partially depends on PPARα, possibly through a similar
impact on PKC [74].
The in vivo signiﬁcance of macrophage PPARα is illus-
tratedbyenhancedatherosclerosisinlow-densitylipoprotein
receptor-deﬁcient mice transplanted with PPARα−/− bone
marrow, which is due to an increased inﬂammatory response
of macrophages [75]. In the same vein, PPARα−/− spleno-
cytes produce signiﬁcantly higher levels of inﬂammatory4 PPAR Research
cytokines in aged mice, both under basal conditions or in the
presence of LPS [76].
2.3.3. PPARβ/δ
In contrast to PPARγ and -α,P P A R β/δ can also be asso-
ciated with M1 (besides M2) and may contribute to the
proinﬂammatory phenotype of these macrophages. Indeed,
under basal conditions PPARβ/δ−/− macrophages display a
reduced expression of some (MCP-1, IL-1β, and MMP9),
but not all (TNFα,I K K β) inﬂammatory mediators. As such,
inﬂammation-driven atherosclerotic lesion formation is sig-
niﬁcantly reduced in PPARβ/δ−/− bone marrow chimeras.
Mechanistically, PPARβ/δ forms a complex with the tran-
scriptional repressor Bcl-6, preventing Bcl-6 from repressing
inﬂammatory genes. However, upon synthetic ligand bind-
ing (e.g., GW501516) PPARβ/δ releases Bcl-6 and inﬂamma-
tion is dampened [77]. On top of that, PPARβ/δ activation
induces the expression of mediators suppressing inﬂamma-
tory cytokine/chemokine action (RGS, TIMP-3), altogether
explaining the beneﬁcial eﬀects of PPARβ/δ agonists in
inﬂammatory diseases such as atherosclerosis [78, 79].
2.4. PPARsandM2activationofmacrophages
PPARs not only antagonize M1 activation, but actually
support M2 activation. Indeed, at least some of the reported
anti-inﬂammatory eﬀects of IL-4 or IL-13 are mediated
through enhanced PPARγ activity [80]. IL-4/IL-13 strongly
increase the production of diﬀerent endogenous PPARγ
ligands (13-HODE, 15-HETE, and 15d-PGJ2)a n dP P A R γ
coactivators (PGC-1β), thereby stimulating the PPARγ
transactivating activity [37, 42, 43, 81]. As a matter of fact,
someofthehallmarkIL-4/IL-13-inducibleM2markers,such
as MMR, arginase I, CD36, and dectin-1, depend on PPARγ
for full induction [42, 43, 82–84]. Following this logic,
administration of PPARγ ligands could be a valuable means
of inducing M2 markers in vivo and altering macrophage
functions[85].Thesigniﬁcanceoftheseﬁndingswasrecently
established in macrophage-speciﬁc PPARγ−/− mice [86].
Although LPS-induced release of IL-6 was not signiﬁcantly
diﬀerent between w.t. and PPARγ−/− macrophages, only in
the PPARγ-deﬁcient cells was IL-4 unable to suppress IL-
6, corroborating the notion that a subset of IL-4-dependent
anti-inﬂammatory responses is regulated by PPARγ [86].
These mice are defective in the in vivo generation of M2
to a similar extent as macrophage-speciﬁc IL-4Rα−/− mice
or STAT6 null mice. As a consequence, these mice are more
resistant to Th2/M2-driven pathologies, such as cutaneous
leishmaniasis.
S i m i l a rt oP P A R γ,P P A R β/δ ablation was shown to
diminishtheM2phenotypeinmacrophages,notablyKupﬀer
cells and adipose tissue-resident macrophages, in vitro
a n di nv i v o( i nP P A R β/δ−/− bone marrow chimeras or
myeloid-speciﬁc PPARβ/δ−/− mice), and to increase inﬂam-
mation.This results in systemic insulin resistance, increased
adipocyte lipolysis, and hepatic dysfunction [49, 87].
Overall, it is clear from previous paragraphs that the
regulation of PPARs by pro- or anti-inﬂammatory signals
is one of the important factors that triggers macrophage
polarization. It is however important to realize that the exact
eﬀects of PPARs on macrophages can depend on the source
from which macrophages have been isolated (mouse versus
human, diﬀerent tissues, diﬀerent pathogenic conditions, in
vitro versus in vivo studies, etc.) and on the maturation stage
of the macrophage population before PPAR activation.
3. M1 MACROPHAGES IN TUMOR INITIATION
Epidemiological studies clearly established a causal link
between chronic inﬂammation—triggered by microbial
infections or autoimmune diseases—and tumor develop-
ment [2–5, 88]. Consequently, prolonged intake of nons-
teroidal anti-inﬂammatory drugs has been proven to lower
cancer incidence [89]. M1 macrophages are central orches-
trators of the inﬂammatory response and are of critical
importance in some of the well-known cancer-predisposing
malignancies: Helicobacter pylori infection for gastric cancer
[90], inﬂammatory bowel disease for colon carcinoma [91],
and hepatitis for hepatocellular carcinoma [92]. Hence,
inﬂammatory macrophages are actively involved in de novo
carcinogenesis and the ﬁrst steps of tumor development
Figure 1.
3.1. Tumor-initiatingroleofNF-κBinmacrophages
The NF-κB transcription factor is the master regulator of
inﬂammation and has been shown to function as a tumor
promoter in inﬂammation-associated cancers [50, 93]. NF-
κB can be activated both in cancer cells and immune
cells, in particular M1 macrophages. The presence of such
macrophages, bearing activated forms of NF-κB and other
inﬂammatorysignalingmoleculessuchasp38MAPK,isseen
in premalignant lesions (e.g., colonic polyps) [94]. Hence, it
is of interest to gain insight into the relative importance of
the NF-κB cellular context (cancer cell versus macrophage)
for carcinogenesis. A number of seminal papers have shed
light on this issue in the past few years. In colitis-associated
colon carcinoma formation, a prototypical example of
inﬂammation-driven carcinogenesis, tumor formation, was
reducedtothe sameextent inmicewith eitheranenterocyte-
speciﬁc or a myeloid cell-speciﬁc defect in the IKKβ-
dependent NF-κB pathway. In the case of the myeloid cells,
NF-κB-mediated carcinogenesis depends on the production
of inﬂammatory mediators that act as tumor-promoting
paracrine factors [95]. In agreement with these ﬁndings,
the absence of SIGIRR/TIR8, a negative regulator of NF-κB,
aggravates colitis-associated carcinogenesis. SIGIRR/TIR8
functions as a tumor suppressor both in colon epithe-
lium and in bone marrow-derived cells [96]. Surprisingly,
even in a model of noninﬂammatory tumor formation
(DEN-induced hepatocarcinogenesis), NF-κBa c t i v a t i o ni n
macrophages (Kupﬀer cells) appears to stimulate tumorige-
nesis through the secretion of hepatomitogens such as TNFα
and IL-6 [97].
Apart from virally or bacterially induced cancers, how
does NF-κB get activated in macrophages during carcino-
genesis? Recent ﬁndings demonstrate an important roleJo A. Van Ginderachter et al. 5
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Figure 1: Simpliﬁed scheme of the role of M1 macrophages in inﬂammation-driven carcinogenesis and the potential anticarcinogenic eﬀect of
PPAR ligands. In the context of chronic pathogen infection or chemically induced chronic inﬂammation, exogenous and/or endogenous
ligands for Toll-like receptors are present, which stimulate NF-κB activation via the MyD88 pathway. Also inﬂammatory cytokines such as
TNFα and IL-1β stimulate NF-κB activatity through their respective cytokine receptors (CRs). Subsequently, NF-κB transcribes a number
of carcinogenic mediators, including IL-6, TNFα, COX-2, and iNOS amongst others. PPAR ligands are able to interfere with the induction
of these inﬂammatory mediators, using diﬀerent mechanisms. Activated PPARγ tranrepresses NF-κB activity, activated PPARα physically
interacts with NF-κB, and activated PPARβ/δ unleashes the transcriptional repressor Bcl-6. Note that the anticarcinogenic actions of the
PPAR agonists are only seen in inﬂammatory tumorigenesis but not in noninﬂammatory carcinogenesis.
for MyD88, the adaptor molecule in TLR and IL-1R
signaling, in inﬂammation-associated or noninﬂammatory
carcinogenesis alike [98–100]. Interestingly, functional poly-
morphisms in TLRs can predispose to certain types of
carcinoma [101]. TLRs can become activated by endogenous
ligands produced during cancer cell necrosis or extracellular
matrix degradation, or—as shown in a transgenic model
of gastric carcinogenesis—by the indigenous bacterial ﬂora
[102]. Another interesting pathway has been suggested by
the Coussens lab, Calif, USA.Myeloid cells could become
activated in response to immunoglobulins, putting the B
cell-myeloid cell axis central in inﬂammation-associated
carcinogenesis [103].
3.2. NF-κB-regulatedmacrophageproducts
responsiblefortumorinitiation
A large body of evidence points to inﬂammatory cytokines
as major culprits for tumor stimulation. In the model of
DEN-induced hepatocarcinogenesis, the estrogen-regulated
diﬀerence in IL-6 production by male versus female Kupﬀer
cells entirely accounts for the gender diﬀerences in tumor
incidence [98]. While IL-6 is a hepatocyte mitogen, TNFα
induces hepatocyte NF-κB activation with a strong impact
on tumorigenesis. Even under noninﬂammatory conditions,
this carcinogenic TNFα is produced by endothelial cells
and Kupﬀer cells [104]. In addition, carcinogen-stimulated
chronic TNFα expression in liver inﬂammatory cells, pre-
sumablyKupﬀercells,hyperactivatesovalcellsthroughTNF-
R1, resulting in liver tumor formation [105]. Comparable
mechanismsareatplayincolitis-associatedcoloncarcinoma,
where macrophage-derived TNFα interacts with TNF-R1 in
an autocrine way, creating an essential inﬂammatory loop
for carcinogenesis [106]. One of the target genes of TNFα-
stimulated NF-κB in this model is COX-2 [107]. COX-
2, via the production of PGE2, strongly promotes colon
carcinogenesis [108]. Importantly, in premalignant lesions
of both mice and humans, COX-2 is almost exclusively
e x p r e s s e di nm a c r o p h a g e s[ 108, 109]. Similarly, the NF-κB
target gene MMP9 is important for skin carcinogenesis and
is exclusively produced by inﬂammatory cells [110]. Finally,
other prototypical inﬂammatory macrophages products,
such as nitric oxide and reactive oxygen species, have all been
shown to contribute to oncogenesis [97, 111, 112].
3.3. Roleofmacrophage-speciﬁcPPARsin
tumorinitiation
Considering the importance of inﬂammatory macrophages
as a trigger of carcinogenesis and the anti-inﬂammatory
function of PPARs in macrophages, it seems logical to
pursue PPAR ligation as a strategy to block the initial steps
of tumor formation. Indeed, some of the most promi-
nent tumor-promoting mediators of macrophages—TNFα,
MMP9,iNOS—areknowntoberepressedbyPPARγ ligation
[53, 113, 114]. In addition, PPARγ ligands, which had no
signiﬁcant eﬀect on tumor cell lines in vitro, were shown to
exert potent inhibitory eﬀects on tumors from the same cells
in vivo, suggesting other targets besides cancer cells in the
tumor-environment [115].6 PPAR Research
In line with this rationale, in vivo administration of
PPARγ,- α,a n dβ/δ agonists invariably reduces tumor
initiation in typical models of inﬂammation-associated
carcinogenesis, such as colitis-driven colon carcinoma [116–
118]. The situation is more blurred in colon cancer induced
by genetic means ( APCMin mice) rather than by inﬂam-
matory stimulation, with contrasting reports describing
tumor stimulation or repression upon PPARγ ligation [119–
121]. A recent study employed genetic means to assess the
role of PPARγ in chemically-induced (inﬂammatory) versus
genetically-induced (noninﬂammatory) colon carcinogene-
sis. Haploinsuﬃciency of the PPARγ gene promotes inﬂam-
matory carcinogenesis but has no eﬀect in APCMin mice
[122]. Similarly opposing data exist on the role of PPARβ/δ
in tumor formation in APCMin mice, even between studies
looking atAPCMin in a PPARβ/δ null background [123, 124].
Recent studies have studied transplantable tumor growth
in PPARα−/− or PPARβ/δ−/− mice. In both cases, tumor
growth was strongly suppressed irrespective of the PPAR
status of the cancer cells, indicating that host PPARα and
PPARβ/δ are important determinants in tumor formation
[125, 126]. In the case of PPARα, absence of the receptor
resulted in overt inﬂammation and neutrophil-mediated
tumor clearance [125]. Hence, the level of PPARα stim-
ulation might instruct the anti- or protumor activities of
inﬂammatory cells: (i) absence of PPARα leads to inﬂam-
matory cell-mediated tumor destruction, (ii) physiological
levels of PPARα stimulation could allow lower, protumoral
levels of inﬂammation, and (iii) strong PPARα stimulation
with agonists could shutdown inﬂammation completely,
prohibiting inﬂammation-driven carcinogenesis. Following
this logic, scenarios (i) and (iii) reduce tumor growth, which
has indeed been demonstrated experimentally [125, 127].
4. M1/M2 MACROPHAGES IN TUMOR PROGRESSION
Establishedtumorsareoftenheavilyinﬁltratedbyleukocytes,
of which tumor-associated macrophages (TAMs) can be a
signiﬁcant portion. The relevance of TAM in tumor biology
is underscored by clinical studies showing a correlation
between TAM abundance and poor prognosis, data which
areparticularlystrongforbreast,prostate,ovarian,andsome
types of lung cancers [128–130]. In addition, macrophage-
deﬁcient mice display reduced progression of tumors to a
more malignant phenotype [131, 132] .T A M sa r ea b l et o
promote tumor progression via several mechanisms, includ-
ing (i) induction of angiogenesis [133], (ii) remodelling
of extracellular matrix [129], (iii) stimulation of cancer
cell proliferation, migration, and invasion [134], and (iv)
inhibition of adaptive immunity [135].
Current knowledge does not allow an unequivocal
classiﬁcation of TAM as prototypical M1 or M2 [28]. While
TAMs are generally considered as anti-inﬂammatory M2,
c h a r a c t e r i z e db ya nI L - 1 0 high/IL-12low cytokine proﬁle and
defective NF-κBa c t i v a t i o n[ 27, 136, 137], these cells are
also known to contribute to angiogenesis and cancer cell
aggressivenessviathesecretionoftheM1-associatedandNF-
κB-regulated mediators, such as TNFα,I L - 1 β, and MMP-
9[ 138–140]. The relative abundance of M1 or M2 markers
in TAM could be related to the phase of tumor progression
[141].
In any case, the relative plasticity and diversity of TAM
makeitdiﬃculttopredicttheeﬀectofPPARligationonthese
cells and on tumor outcome. In a mouse lymphoma model,
we described an increased PPARγ mRNA expression in M2-
orientedTAMandsplenicmacrophagesdiﬀerentiatedfroma
monocytic CD11b
+Gr-1+ precursor [135, 142]. Remarkably,
stimulation of TAM with PPARγ ligands completely reverses
TAM-mediated T-cell suppression,via an as yet unknown
mechanism.
5. CONCLUDING REMARKS
In recent years, it has become clear that macrophages and
other myeloid cells, such as mast cells and neutrophils, are
central orchestrators of both tumor initiation and tumor
progression. With the advent of the M1/M2 concept of
macrophage activation, it has become clear that inﬂamma-
tory M1 signiﬁcantly participate in carcinogenic processes
initiated by strong inﬂammatory stimuli, such as pathogens
or certain chemicals. This ﬁnding opens a window of
opportunity for the use of PPARγ,-α,a n dβ/δ agonists, some
of which are already in clinical use for metabolic disorders,
in chemoprevention of de novo tumor formation in patients
at risk. However, the applicability of these compounds as
anticancer agents is confounded by the often confusing
ﬁndings in mice. In our view, confusion is the consequence
ofaninsuﬃcientinsightintheparticipationofinﬂammatory
cells in the models under study, making it diﬃcult to
extrapolate ﬁndings from one model to another. Overall, we
feel that the usefulness of PPAR agonists is directly correlated
with the extent to which inﬂammation is a driving force
for carcinogenesis. Though this might hold true for the
initial steps of tumor formation, the situation becomes more
complicatedinestablishedtumors.Consideringtheplasticity
and heterogeneity of tumor-associated macrophages, with a
mixture of M1 and M2 markers and considerable diﬀerences
between tumor types [28], it is more diﬃcult to envisage
a broad applicability of PPAR ligands for the modulation
of TAM. However, treatment of certain typical macrophage-
driven malignancies, such as breast carcinoma, could poten-
tially beneﬁt from these compounds.
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